Over 2350 Total Lots Up For Auction at Four Locations - NJ Cleansweep 09/29, TX 09/30, FL 10/06, NY 10/07

Assessing the reimbursement challenges facing radiopharmaceuticals

por Gus Iversen, Editor in Chief | June 25, 2021
Molecular Imaging
From the June 2021 issue of HealthCare Business News magazine

As Congress contemplates additional policies to support our healthcare system, it is necessary to ensure that Medicare beneficiaries (as well as all Americans) have access to newer precision diagnostic radiopharmaceuticals. Therefore, we will continue to urge Congress to consider enacting the FIND Act.

HCB News: Will reimbursement to be a big topic at the upcoming SNMMI meeting?
MG: Yes. We are at a very crucial juncture with uncertainties regarding the path of recovery from the pandemic. Our members are deeply concerned about inadequate reimbursement, and our industry partners — who are developing innovative nuclear medicine procedures — need to be informed about the various efforts underway to ensure financial viability of their efforts. Therefore, reimbursement will certainly be a big topic at the upcoming SNMMI meeting.

HCB News: What can healthcare leaders do to make their own voices heard and become more engaged with ongoing reimbursement debates?
MG: SNMMI and its coalition partners are encouraging healthcare leaders, patient groups and industry stakeholders to engage with their elected officials in the Congress to support the FIND Act. We encourage healthcare leaders to participate in the virtual fly-ins that are being organized for coming months.

Back to HCB News

You Must Be Logged In To Post A Comment